Date:2/27/2013

"could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the anticipated timeframes relating to the development of BEMA Buprenorphine and BNX) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

BDSI^® and BEMA^® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo is a trademark owned by BioDelivery Sciences International, Inc.  ONSOLIS^® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.

© BioDelivery Sciences International, Inc.  All rights reserved.

'/>"/>

SOURCE BioDelivery Sciences International, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
2. BioDelivery Sciences Announces Completion of BNX Safety Study
3. BioDelivery Sciences Announces $40 Million Registered Financing
4. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
5. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
9. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
10. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
11. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study